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Increased proliferation rates as well as resistance to apoptosis are considered major obstacles for the treatment of
patients with chronic myelogenous leukemia (CML), thus highlighting the need for novel therapeutic approaches.
Since senescence has been recognized as a physiological barrier against tumorigenesis, senescence-based
therapy could represent a new strategy against CML. DNA demethylating agent 5-aza-2′-deoxycytidine (DAC) was
reported to induce cellular senescence but underlying mechanisms remain to be elucidated. Here, we report that
exposure to DAC triggers senescence in chronic leukemia cell lines as evidenced by increased senescence-
associated β-galactosidase activity and lysosomal mass, accompanied by an up-regulation of cell cycle-related
genes. We provide evidence that DAC is able to decrease telomere length, to reduce telomerase activity and to
decrease human telomerase reverse transcriptase (hTERT) expression through decreased binding of c-myc to the
hTERT promoter. Altogether, our results reveal the role of c-myc in telomere-dependent DAC-induced senescence
and therefore provide new clues for improving chronic human leukemia treatments.
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Chronic myeloid leukemia (CML) is a clonal myeloproliferative
disorder characterized by the Philadelphia chromosome translocation.
This translocation results in the BCR-ABL oncogene that encodes a
tyrosine kinase driving expansion of myeloid progenitors cells [1].
Increased proliferation as well as apoptosis resistance are among the
mechanisms responsible for myeloid cell expansion [2]. Thus, there has
been considerable interest in developing new strategies to override
apoptosis resistance, eliminate tumor cells and consequently improve
therapeutic outcome of resistant CML patients. Since senescence is now
recognized as a crucial tumor suppressor mechanism that qualitatively
equals programmed cell death [3], senescence-based therapy in CML
could represent a new, largely unexplored, therapeutic approach.
In contrast to tumor stem cells, healthy somatic cells have a limited
proliferative lifespan after which they stop dividing and enter a terminal
state of irreversible growth arrest called replicative senescence. Senescent
cells are both morphologically and functionally altered. Indeed, they are
characterized by the acquisition of flattened and enlarged cell
morphology, an increase in senescence associated-β-galactosidase
(SA-β-gal) activity, and a modulation of cell cycle-regulated geneexpression [4]. Stress-induced premature senescence (SIPS) closely
resembles replicative senescence [5], and can be triggered by various
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Figure 1. DAC elicits senescence in CML cells. (A) DAC increases SA-ß-gal activity in K-562 cells. Data are the mean (±SD) of 3
independent experiments. * P b 0.05, ** P b 0.01 versus control (two-way ANOVA). (B to H) K-562, MEG-01 and KBM-5 cells were cultured
in presence or absence of 2 μMDAC for the indicated period of time. “a” and “s” refer to adherent and suspension MEG-01 populations,
respectively. (B) Cytochemical detection of SA-ß-gal activity. (C) Percentage of SA-β-gal-positive cells. The positive control (+) corresponds
to K-562 cells treated with 80 nM doxorubicin for 72 hours. (D) Flow cytometry determination of SA-ß-gal. Numbers represent mean
fluorescence intensity. (E)Morphological analysis.White arrows indicate vacuoles andblack arrows indicate bulbous protrusions. (F) Number
of cells exhibiting vacuoles as a percentage of the total cell population. (G) Analysis of lysomal mass with pictures representing the merged
signal of LysoTracker Red (lysosomes) and Hoechst (nuclei). (H) Lysosomal mass area quantification. Results represent the mean ± SD of
three independent experiments. All pictures are representative of three independent experiments. * P b 0.05, ** P b 0.01 versus control (one-
way ANOVA).
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Interestingly, several observations indicate that telomere shortening to a
critical length as well as uncapped telomere(s) may trigger SIPS [7].
Human telomerase is a ribonucleoprotein DNA polymerase that
extends eukaryotic chromosome ends with telomeric (TTAGGG)n
sequences to compensate for telomere erosion [8]. The enzyme is
expressed in most human cancer and malignant cell lines, whereas in
most normal somatic human cells its activity is weak or not detectable
[9]. This enzyme consists of two essential components: the human
telomerase reverse transcriptase (hTERT), which encodes the catalytic
component, and the telomerase RNA, providing the template for
telomere synthesis [10]. Telomerase activity is mainly regulated at
hTERT transcriptional level. In particular, several groups have indicatedthat c-myc is a key transcriptional regulator of hTERT. Indeed, the
hTERT proximal promoter harbors two E-boxes that are binding sites
for c-myc [11]. In addition, c-myc overexpression has been reported to
directly up-regulate hTERT mRNA levels [12].
Hypermethylation is considered one of the major epigenetic
modifications involved in aberrant transcriptional silencing of tumor
suppressor genes in human malignancies [13,14]. The potential
reversibility of epigenetic abnormalities encouraged the development
of pharmacological inhibitors of DNA methylation such as decitabine
(5-aza-2’-deoxycytidine, DAC) as an anti-cancer agent. DAC is
currently undergoing preclinical and clinical trials for leukemia either
use alone or in combination with other epigenetic or conventional
anti-neoplastic drugs [15]. Encouraging results were achieved against
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Neoplasia Vol. 16, No. 6, 2014 Grandjenette et al. 513hematologic malignancies and especially in CML patients [16,17]. In
vitro studies have shown the ability of this compound to induce DNA
hypomethylation, re-expression of aberrantly silenced genes, cell cycle
perturbation, apoptosis and differentiation, and increased sensitivity
of cancer cells to conventional chemotherapeutic drugs [18,19].
However, in vivo mechanisms involved in these processes have not
been clearly elucidated.
Interestingly, we recently provided evidence that DAC has the
potential to induce senescence in leukemia cells. In particular, we
demonstrated that DAC-treated CML cells exhibit an increased SA-β-
gal activity and specific changes in cell morphology [19]. In the
current study, we confirmed the induction of cellular senescence after
DAC exposure in CML cell lines and characterized the mechanisms
involved in this process. We reported that DAC-treated CML cells
display morphological features associated with a senescent phenotype,
especially an enlarged morphology, a vacuole-rich cytoplasm and an
up-regulation of cell cycle-dependent genes controlling the senescence
program. We further pointed out that DAC-induced senescent cells
exhibited telomere shortening, decreased telomerase activity as well as
transcriptional down-regulation of hTERT due to reduced c-myc
binding to the hTERT promoter.Materials and Methods
Cell Culture and Drug Treatments
Cell lines were purchased from Deutsche Sammlung für Mikroorga-
nismen und Zellkulturen (DSZM; Braunschweig, Germany). K-562,
MEG-01 and U-937 cells were cultured in RPMI 1640 (Lonza,
Verviers, Belgium), supplemented with 10% fetal calf serum (FCS;
Lonza) and 1% antibiotic–antimycotic (Lonza). KBM-5 cells were
cultured in IMDM (Lonza) supplemented with 15% FCS and 1%
antibiotic–antimycotic. Peripheral blood mononuclear cells (PBMCs)
from healthy donors were isolated and cultured as previously described
[19]. DAC, 5-azacytidine, etoposide and doxorubicin were purchased
from Sigma-Aldrich (Bornem, Belgium). Cells were treated daily with
DAC and 5-azacytidine. Culture mediumwas changed every three days
of treatment to maintain physiological growth rates.
SA-β-gal Assay
SA-β-gal activity was measured as previously reported [19]. K-562
cells treated with 80 nM doxorubicin for 72 hours were used as a
positive control of senescence induction. SA-β-gal activity was also
evaluated by flow cytometry, using 33 μM fluorogenic substrate 5-
dodecanoylaminofluorescein di-β-D-galactopyranoside (C12FDG;
Invitrogen, Tournai, Belgium) in cells pretreated with 100 nM
bafilomycin A1 (Sigma-Aldrich).
Morphological Analysis
Cells were spun onto a glass slide for 4 min at 800 g using a
Shandon Cytospin 4 (Thermofisher, Erembodegen, Belgium), fixed
and stained with the Diff-Quick stain kit (Dade Behring S.A.,
Brussels, Belgium) according to the manufacturer’s procedure. Images
were acquired using a Leica DM2000 equipped with a DFC420C
camera and Leica FireCam software.
Immunofluorescence Microscopy
To assess lysosomal cellular distribution, 5.106 cells were stained
for one hour with 50 nM Lysotracker Red (Invitrogen).
DNA damage accumulation was monitored by analysis of the
γH2AX foci distribution. Immunostaining was performed as
previously described [20]. Cells were incubated overnight at 4°C
with anti-γH2AX antibody (Millipore, Brussels, Belgium), washed
and subsequently stained with an Alexa Fluor® 488-conjugated anti-
mouse antibody (Invitrogen) for 1 h at room temperature.
Nuclei were stained by incubation with 10 μg/ml Hoechst 33342
(Invitrogen) for 15 min at 37°C. Fluorescence microscopy was
realized with a cell^M imaging station from Olympus (Aartselaar,
Belgium). Lysosomal area quantifications were performed using
ImageJ software (rsbweb.nih.gov/ij/).
Cell Cycle Analysis
Samples were washed with 1X PBS and fixed with cold 70% ethanol.
Then, cells were treatedwith RNase A (10 μg/ml) (Roche, Luxembourg,
Luxembourg) and stained with 1 μg/ml of propidium iodide (BD
Biosciences, Erembodegen, Belgium) for 30 min at room temperature in
the dark. All samples were then processed using flow cytometry.
RNA Expression Analyses by Q-RT-PCR
Total RNA was extracted using NucleoSpin RNA II columns
(Macherey-Nagel, Hoerdt France) according to the manufacturer’s
instructions. cDNA was synthesized by reverse transcription of 1 μg
total RNA with M-MLV Reverse Transcriptase, RNase H Minus,
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Netherlands) using oligo(dT) primers (Promega). cDNAs were used
as template for subsequent quantification by real-time PCR in areaction mixture containing 1X Power SYBR® Green PCR Master
Mix (Applied Biosystems, Halle, Belgium), and 0.1 μM of each
primer (sequences available on request). Amplification was performed
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Neoplasia Vol. 16, No. 6, 2014 Grandjenette et al. 515on an ABI 7300 real-time PCR system (Applied Biosystems). The
amount of target gene was normalized to the endogenous level of β-
actin using the 2-ΔCT method.
Protein Extraction and Western Blot
Histone isolation was performed in acidic conditions [21]. Whole
cell extracts were prepared using M-PER® (Thermofisher) according to
the manufacturer’s instructions. Protein concentration was determined
using the Bradford assay (Bio-Rad, Nazareth Eke, Belgium). Proteins
were resolved by SDS–PAGE andWestern Blots were realized using the
following primary antibodies: anti-β-actin (Sigma-Aldrich), anti-c-myc,
anti-p16, anti-p19, anti-p21, anti-p27 (Santa Cruz, Boechout,KBM-5 
MEG-01s 
K-562 
DA
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Figure 1. (cBelgium), anti-γH2AX, anti-hTERT (Millipore) [22]. Proteins of
interest were detected with ECL Prime Western Blotting Detection
System reagent (GE Healthcare) using an ImageQuant LAS 4000 mini
(GE Healthcare).
Relative Telomere Length Assays
Relative telomere length was assessed by flow-fluorescent
in situ hybridization with a fluorescein-conjugated PNA probe
using the Telomere PNA Kit/FITC (Dako Denmark A/S,
Heverlee, Belgium) according to the manufacturer's protocol.
Quantification of relative telomere length was carried out by
flow cytometry.C (days) 
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previously published with few modifications [23]. Genomic DNA was
extracted using the DNeasy® Blood and Tissue Kit (Qiagen, Venlo, The
Netherlands) according to manufacturer’s instructions. Twenty
nanograms ofDNAwere used as template for subsequent quantification
by real-time PCR in a reaction mixture containing 1X Power SYBR®
Green PCRMasterMix (Applied Biosystems), using the primers (written
from 5’ to 3’) for: telomere, forward: ACACTAAGGTTTGGGTTTG
GGTTTGGGTTTGGGTTAGTGT and reverse: TGTTAGGTA
TCCCTATCCCTATCCCTATCCCTATCCCTAACA; RNA poly-
merase II promoter, forward: CTTCTTCCTCCCCCAAAAAC and
reverse: GGGAAATAAGGAGCGAAAGG. PCR conditions used for
the amplification with telomere primers were step 1: 95°C for 10 min;
step 2: cycles of 95°C for 15 s, 49°C for 15 s; step 3: 40 cycles of 95°C
for 15 s, 60°C for 15 s, 70°C for 1 min. PCR conditions used for the
40-cycle amplification with RNA polymerase II primers were as
followed: 95°C for 15 s, 60°C for 1 min after an initial step of 95°C for
10 min. Amplification and detection were carried out using the Applied
Biosystems 7300 Real-time PCR system. Relative telomere length was
calculated as a telomere/RNA polymerase II ratio with the value for
untreated cells set to 1.
Telomerase Activity Assay
Telomerase activity was measured using the Telomerase PCR
ELISA kit (Roche) according to the manufacturer's protocol. Thepositive control (human kidney 293 cell extract) was supplied by
the manufacturer.
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were carried out using c-myc (Santa Cruz) and
H3K4Me3 (Millipore) antibodies [20]. Primers were targeting the c-myc
binding site within the basal region of hTERT promoter.
Flow Cytometry Acquisition and Analysis
Flow cytometry acquisitions were performed on a FACSCalibur
(BD Biosciences) using Cellquest software (BD Biosciences). Data
were analyzed using FlowJo software (Treestar, Ashland, OR, USA).
RNA Interference Assays
Small interfering RNAs (siRNAs) were obtained from Qiagen:
CDKN2D-1 (SI00287707), CDKN2D-2 (SI00287714), c-myc-1
(SI00300902), c-myc-2 (SI02662611), control siRNA (AllStars
Negative Control siRNA). Cells were transfected at 80% confluence
with 10 nM siRNA and HiPerFect Transfection reagent (Qiagen)
according to the manufacturer’s instructions.
Methylation-Specific PCR
Genomic DNA was isolated using the Dneasy® Blood and Tissue
Kit (Qiagen, Venlo, The Netherlands) and then subjected to
sodium bisulfite conversion using the EpiTect® Bisulfite Kit
(Qiagen) according to manufacturer’s instructions. Methylation-
specific PCR (MSP) were carried out as previously described [20].
DNA was amplified using the following primers specific for
methylated (M) or unmethylated (U) sequences targeting: (i) the
CCCTC-binding factor (CTCF) binding region in hTERT with
hTERT-1 M (Forward 5’-GCGCGAGTTTTAGGTAGC-3’, re-
verse 5’-CTCGCGATAATAACTACGCA-3’) and hTERT-1UM
(Forward 5’-GGTGTGAGTTTTAGGTAGT-3’, reverse 5’-
CCTCACAATAATAACTACACA-3’); (ii) the basal promoter of hTERT
with hTERT-2 M (Forward 5’-GGATTCGCGGGTATAGAC-3’,
reverse 5’-CGCGAAAAAAACGAAACTA-3’) and hTERT-2UM
(Forward 5’-AGTGGATTTGTGGGTATAGAT-3’, reverse 5’-
CCACACAAAAAAAACAAAACTA-3’); (iii) the 1st exon of CDKN2D
with CDKN2D-1 M (Forward 5’- ATTCGGTTTTTAAGGGGC-3’,
reverse 5’-GACTACGCTACTCTCCCGTC-3’) and CDKN2D-
1UM (Forward 5’-AGATTTGGTTTTTAAGGGGT-3’, reverse 5’-
CCAACTACACTACTCTCCCATC-3’); and (iv) the basal promoter
of CDKN2D with CDKN2D-2 M (Forward 5’-AAAATTTCGT
TATTGTCGGC-3’, reverse 5’ATAACCAATAACTACGCGTCG-3’)
and CDKN2D-2UM (Forward 5’-GAAAATTTTGTTATTGTTGGT-
3’, reverse 5’-CATAACCAATAACTACACATCA-3’.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism
6.0 software. One-way and two-way ANOVA followed by the
Holm-Sidak multiple comparison tests were used for statistical
comparisons. p-values below 0.05 were considered as statisti-
cally significant.
Results
DAC Elicits Senescence in CML Cells
Previously, we highlighted a mixed population of suspension and
adherent MEG-01 CML cells after DAC exposure [19]. Accordingly,
to further examine the mechanisms of senescence induction by DAC
Control 
 Day 1 
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Figure 2.DAC induces an increase in the expression of key cell cycle regulators of the senescence program. K-562 andMEG-01 cells were
treated with 2 μM DAC for the indicated period of time. “a” and “s” refer to adherent and suspension MEG-01 populations, respectively.
(A, B) Cell cycle analysis. (C, D) Analyses of mRNA and protein expression levels of cell cycle regulators. Cell cycle graphs and blots are
representative of three independent experiments. Data are the mean ± SD of three independent experiments. * P b 0.05, ** P b 0.01
versus control (one-way ANOVA).
Neoplasia Vol. 16, No. 6, 2014 Grandjenette et al. 517in CML, we chose to analyze the two MEG-01 cell populations
separately from the third day of treatment.
First, SA-β-gal activity was evaluated in K-562 CML cells with or
without different doses of DAC from 0.125 to 2 μM up to 6 days.
Senescent cells were identified as blue-stained cells by standard light
microscopy. As shown in Figure 1A, microscopy analyses revealed thatsenescence induction was increased dose-dependently. The maximum
of senescence was observed in K-562 cells exposed to 1 and 2 μMDAC
for 6 days with 80 % of SA-β-gal positive cells. In this regard, we chose
to treat CML cells with 2 μM of DAC for further experiments.
SA-β-gal activity was compared in K-562, MEG-01 and KBM-5
CML cells with or without DAC treatment. K-562 cells treated with
Control 
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 Day 2 
 Day 3 
 Day 4 
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Figure 2. (continued).
518 5-aza-2′-deoxycytidine promotes senescence in CML Grandjenette et al. Neoplasia Vol. 16, No. 6, 2014doxorubicin, a known inducer of cellular senescence [24], were used
as a positive control. As expected, doxorubicin induced an increase in
SA-β-gal activity in K-562 cells compared to untreated cells (Figure 1,
B and C). Similarly, DAC treatment resulted in a time-dependent
increase of SA-β-gal activity in K-562, MEG-01 and KBM-5 cells.
Indeed, up to 74, 30, 81 and 85% of K-562, suspension MEG-01,
adherent MEG-01 and KBM-5 cells, respectively, were significantly
positive for SA-β-gal staining after 6 days of culture with DAC.
Remarkably, the kinetic of induction of SA-β-gal activity in KBM-5
cells is slower than in K-562 and MEG-01 cells. Indeed, while only
7% of KBM-5 cells were positive for SA-β-gal staining after 3 days of
DAC treatment, 60% of K-562 and MEG-01 cells were positive.
Nevertheless, in the three CML cell lines, approximately 80% of cells
were SA-β-gal positive after 6 days of treatment.SA-β-gal activity was further quantified in K-562 and MEG-01
cells by flow cytometry using C12FDG (Figure 1D). Results showed
that, after 4 days of DAC treatment, K-562, adherent and suspension
MEG-01 cells exhibited a 2.5, 3.1 and 2.5-fold increase in SA-β-gal
compared to untreated cells, respectively. Therefore, these data
support our previous results (Figure 1, B and C).
Senescence induction was confirmed by assessment of cell
morphology after May-Grünwald Giemsa staining in DAC-treated
K-562, MEG-01 and KBM-5 cells. As shown in Figure 1D, the size
of CML cells increased and bulbous protrusions became visible after
one day (Figure 1E, black arrows). Two-day-treated K-562 cells
exhibit numerous small cytoplasmic vacuoles (Figure 1E). After
longer treatment, more than 94% of K-562 cells exhibit vacuoles
(Figure 1F). In addition, vacuole number decreased while their
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Neoplasia Vol. 16, No. 6, 2014 Grandjenette et al. 519volume increased. Analysis of May-Grunwald Giemsa-stained KBM-
5 cells after 3-day exposure to DAC indicate that the relatively scarce
cytoplasm of the cells contained also many little vacuoles (Figure 1E).
After longer treatments, cells presented either bulbous protrusions or
little cytoplasmic protrusions (white arrows). In addition, the
percentage of cells containing vacuoles as well as the vacuole number
was remarkably increased in a time-dependent manner (Figure 1, E
and F). Similarly, approximately 30% of DAC-treated MEG-01 cells
in suspension exhibited cytoplasmic vacuoles from day 1 (Figure 1F).
These cells were larger than untreated cells and also characterized by
the presence of bulbous protrusions (Figure 1E, black arrows).
Since senescent cells typically exhibit an increase in lysosome size
and number, we further assessed the cellular distribution of lysosomes
in CML cells. K-562, MEG-01 and KBM-5 cells with or without
DAC treatment were stained with Lysotracker Red and microscopy
observations indicate that the lysosomal compartment is more
prominent in K-562 and MEG-01 cells after 3 days of treatment
(Figure 1G). Indeed, 6 day-DAC-treated K-562 and MEG-01 cells
exhibited a 3.3 and 5.8-fold increase in the lysosomal area compared
to untreated cells, respectively (Figure 1H). DAC-treated KBM-5
cells also exhibited an increased lysosomal mass from day 6 compared
to control cells (Figure 1, G and H). After 10 days of treatment,
KBM-5 cells showed a 2-fold increase in the lysosomal mass.DAC Induces Increased Expression of Key Cell Cycle Regulators
of the Senescence Program
Senescence is commonly associated with changes in the expression
levels of various cyclin-dependent kinase inhibitors resulting in an
irreversible cell cycle arrest [25]. To assess the effect of DAC on cell
cycle, DNA content of DAC-treated K-562 andMEG-01 cells exposed
to DAC up to 10 and 8 days, respectively, was analyzed by flow
cytometry. As shown in Figure 2, A and B, DAC treatment induced a
transitional accumulation inG2/M cell cycle phase in K-562 cells at day
1 and day 2 with an equal percentage of cells in G2/M at day 1 and day
4. Results also revealed that the sub-G1 population was increased in a
time-dependent manner after 8 days of exposure with DAC. Indeed,
the number of K-562 cells in sub-G1 phase was increased from 6.3 to
62.8% in control and 10-day treated K-562 cells, respectively. No cell
cycle phase-specific accumulation was observed in both suspension and
adherent MEG-01 populations after DAC exposure (Figure 2, A and
B). Nevertheless, flow cytometry analyses indicate a time-dependent
accumulation of suspension cells in sub-G1 phase from day 6, reaching
60.8% after 10 days of treatment.
Then, the expression of key cell cycle-related genes involved in the
senescence process was evaluated in K-562 and MEG-01 cells by real-
time PCR. As shown in Figure 2C, DAC-treatedK-562 cells displayed a
significant increased expression of CDKN1A (p21WAF1/CIP1) and
CDKN1B (p27Kip1) genes, two G1-S and G2-M phase-checkpoint
regulators. Nevertheless, K-562 cells do not express CDKN2A
(p16INK4A) gene due to a locus deletion (data not shown). Similarly,
DAC treatment induced a time-dependent increase of CDKN1A and
CDKN1B in MEG-01 cells. Expression of the G1 cell-cycle inhibitor
CDKN2A was increased in DAC-treated MEG-01 cells. In addition,
p27 protein levels were increased in a time-dependent manner from day
3, in K-562 andMEG-01 cells exposed to DAC (Figure 2D). Similarly,
p16 protein expression was increased in DAC-treated K-562 cells in a
time-dependent manner. Nevertheless, Western Blot analyses did not
show any induction of p21 in the two CML cell lines (data not shown).
Therefore, senescence induction was associated with an increased
expression of multiple cell cycle regulators in K-562 andMEG-01 cells.
DAC-Induced Senescence is not Associated with DNA
Damage Accumulation
We further addressed whether DAC-induced senescence in CML
is associated with the activation of DNA damage signals. Thus, we
examined the γH2AX level, the earliest known cellular response to
DNA damage localized at double strand breaks (DSB) sites [26], in K-
562 cells exposed to DAC. Microscopy (Figure 3A) and Western Blot
(Figure 3B) analyses revealed that the proportion of γH2AX-positive
cells in DAC-treated K-562 cells was not changed up to 6 days of
DAC treatment compared to untreated K-562 cells. In contrast,
γH2AX expression could be clearly detected after senescence
induction since it appeared after 8 days of treatment.DAC-Induced Telomere Shortening in CML Cell Lines is
Associated With Transcriptional Down-Regulation of hTERT
In order to assess involvement of telomere length in DAC-induced
senescence, we evaluated the relative telomere length by flow
cytometry (Figure 4A), and by real-time PCR (Figure 4B). Flow
cytometry analyses indicate that DAC causes telomere shortening in
K-562 cells after 3 days of treatment. Indeed, relative telomere length
was reduced by 40% in 3-day-DAC treated K-562 cells compared
to control cells. Remarkably, relative telomere length in DAC-treated
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analyses confirmed that telomere shortening was significantly
increased after DAC exposure. Flow cytometry analyses demonstrated
that a 6-day DAC treatment period induced a decrease by 50 and
32% of relative telomere length in MEG-01 and KBM-5 cells,
respectively. Real-time PCR analyses indicate that telomere shorten-
ing was time-dependent in both cell lines.
Telomerase activity was then assessed in K-562, MEG-01 and
KBM-5 cells exposed to DAC up to 6 days using a modified TRAP
assay to evaluate if the reduction of telomere length in DAC-treated
cells was due to telomerase modulation. K-562 cells presented a 2.6-
fold decrease in telomerase activity after 3 days of treatment
(Figure 4C). A decrease in telomerase activity was also observed in
DAC-treated KBM-5 and MEG-01 cells but it occurred only after
6 days of treatment. Indeed, KBM-5 as well as adherent and
suspension MEG-01 cells exhibited a 2.2-, 2.6- and 3.5-fold reduced
telomerase activity, respectively. According to reduced telomere
length in PBMCs (Figure 4A), telomerase activity in PBMCs was
lower than in K-562, MEG-01 and KBM-5 cells.
The expression pattern of hTERT is considered to be a rate-
limiting determinant of the enzymatic activity of human telomerase.
Thus, hTERT expression was assessed by real-time PCR. DAC
induced a significant time-dependent down-regulation of hTERT
expression from 2 days of DAC treatment in K-562 and MEG-01
cells (Figure 4D). In addition, the level of hTERT mRNA is
drastically reduced after 4 days in DAC-treated KBM-5 cells.
Consequently, these results suggest that DAC reduced hTERT
expression in CML cells and that telomerase activity closely correlated
with hTERT expression.DAC Reduces hTERT Expression Through Decreased Binding
of c-myc to the hTERT Promoter in CML Cells
Since c-myc acts as a key transcriptional activator of hTERT [27],
we further elucidated the mechanism leading to hTERT down-
regulation after DAC treatment by analyzing the binding of c-myc to
the hTERT promoter (Figure 5A). ChIP assays revealed that the
histone methylation mark H3K4me3, a hallmark of active promoters
and actively transcribed regions, was enriched at the hTERT
promoter in untreated K-562 cells. However, H3K4Me3 decreased
at the hTERT promoter after 4 days of DAC treatment, and
correlated with decreased hTERT expression. We also demonstrated a
decreased binding of c-myc to the hTERT promoter after 3 days of
DAC treatment. This binding was dramatically impaired after longer
exposure to DAC. These results suggest that DAC reduces hTERT
expression at least in part through decreased binding of c-myc to
hTERT promoter in CML cells.
We further attempted to determine whether decreased binding of
c-myc to the hTERT promoter could be due to an alteration of c-myc
expression in DAC-treated K-562 cells. As shown in Figure 5B, c-myc
protein expression remained unaffected after one day of DAC treatment
but was drastically decreased after 2 days in K-562 cells. The decrease of
c-myc protein was due to a transcriptional down-regulation as shown by
real-time PCR from day 2 in K-562 cells (Figure 5C).
In order to assess whether c-myc is involved in the transcriptional
regulation of hTERT in our cell model, we down-regulated c-myc
expression using siRNAs and evaluated its effect on hTERT
expression. Results demonstrated a tight correlation between c-myc
and hTERT expression levels at both RNA and protein levels
(Figure 5D).
DAC (Days) 
0 
3 
6 
8 
DAC (days) 
A 
0 1 2 3 4 6 
Control 
+ - 
-H2AX 
H2AX 
8  
B 
Hoechst Merged H2AX
Figure 3. DAC-induced senescence is independent of DNA damage accumulation. K-562 were cultured in presence of 2 μM DAC for the
indicated period of time. (A) Cells were assessed for γH2AX phosphorylation (green) and counterstained with Hoechst 33342 (blue).
Pictures are representative of three different experiments. (B) Western Blot analysis of γH2AX expression. U-937 cells left untreated (−) or
treated with 100 μM etoposide for 4 h (+). Blots are representative results of three independent experiments.
Neoplasia Vol. 16, No. 6, 2014 Grandjenette et al. 521CDKN2D (p19INK4D) has been described as a negative regulator
of c-myc [28]. In this context, we investigated whether DAC may
affect CDKN2D expression in K-562 cells. Results indicate that
CDKN2D expression is significantly increased in DAC treated K-562
cells in a time-dependent manner (Figure 5, E and F).
We further attempted to determine whether c-myc repression in
DAC-treated K-562 cells could be related to CDKN2D up-
regulation. For this purpose, the effect of CDKN2D silencing
using siRNAs on c-myc expression was investigated. Surprisingly, we
found that CDKN2D knockdown did not alter c-myc at both RNA
and protein levels in our cell model (Figure 5G).
The Expression of hTERT, but not CDKN2D, is Modulated
Through Epigenetic Mechanisms in DAC-Treated K-562 Cells
Since DAC is a demethylating agent, we hypothesized that DAC
could trigger senescence in CML cells via epigenetic mechanisms. To
verify this hypothesis, we further analyzed whether 5-azacytidine,
another demethylating agent, could induce the senescence program in
K-562 cells. As shown in Figure 6A, 5-azacytidine treatment triggers a
dose-dependent increase in SA-β-gal activity. Nevertheless, the kinetic
of senescence induction was slower with 5-azacytidine than with DAC
treatment. Indeed, K-562 cells display a significant increased SA-β-gal
activity from 0.125 μM 5-azacytidine after 6 days of treatment.
In order to determine whether hTERT down-regulation could also
be due to an epigenetic regulation, we assessed the methylation status
of hTERT promoter as well as the CTCF binding region of hTERT
by MSP. Methylation specificity was demonstrated with fullyunmethylated, methylated converted as well as with unmethylated
unconverted DNA (Figure 6B). MSP revealed that the basal promoter
of hTERT was not methylated in K-562 cells and that DAC did not
change this state. In contrast, the CTCF binding region in hTERT
was partially methylated and, interestingly, DAC treatment reduced
dramatically its methylation from day 3.
Since we provided evidence that CDKN2D expression was
significantly increased in DAC treated K-562 cells, we then
attempted to elucidate the mechanisms leading to CDKN2D
modulation. For this purpose, CDKN2D expression was
monitored in K-562 cells treated with various concentrations of
DAC from 0.0625 to 2 μM. As shown in Figure 7A, K-562 cells
exposed to increasing doses of DAC exhibit increased CDKN2D
gene expression.
Since DAC triggered an increase in CDKN2D expression in a dose-
dependent manner, we hypothesized that methylation of CDKN2D
promoter region could correlate with the lack of CDKN2D expression in
K-562 cells. To test this hypothesis, CDKN2D methylation status was
assessed by MSP. Methylation specificity was demonstrated with fully
unmethylated, methylated converted as well as with unmethylated
unconverted DNA (Figure 7B). Results revealed that DAC treatment did
not have any effect on CDKN2D promoter methylation, which is already
unmethylated in untreated cells.
Discussion
Altogether, we provided evidence that DAC-induced senescence in
CML cells was associated with decreased telomerase activity as well as
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522 5-aza-2′-deoxycytidine promotes senescence in CML Grandjenette et al. Neoplasia Vol. 16, No. 6, 2014reduced hTERT transcriptional expression through decreased
binding of c-myc to the hTERT promoter.
Senescence induction was revealed by the significant increase in
SA-β-gal activity, the enlarged and flattened morphology as well as the
markedly increase of the lysosomal compartment, which consist of
characteristic markers for senescent cells [29]. To our knowledge, no
study has focused on senescence induction after DAC treatment in
leukemia cells. Although other studies have suggested that DAC may
induce senescence in different solid cancer cells, the authors did not
investigate in details the mechanisms involved in the senescence
program [30,31].
Several lines of evidence indicate that the senescence program may
be accompanied by DNA damage response, triggered either by
dysfunctional telomeres or DSBs [32]. In this study, γH2AX foci
formation was distinguished only after senescence induction in the
senescent DAC-treated CML cells suggesting that the DNA damage
response was not involved in the senescence program. We have
previously reported that the DAC-induced senescence was followed
by apoptosis induction after sustained exposure to DAC [19].
Accordingly, here, we pointed out that the formation of γH2AX focioccurred only after eight days of treatment in CML cells concomitantly
with apoptosis induction.
Cyclin-dependent kinase inhibitors such as CDKN2A (p16INK4A),
CDKN1A (p21WAF1/CIP1) and CDKN1B (p27Kip1) are key effectors of
the cellular senescence program [25]. Consistently, we further showed
that DAC-induced senescence was accompanied by significant increase in
the expression of p16 and p27 at RNA and protein levels. Accordingly,
up-regulation of CDKN1A, CDKN1B mRNA as well as p16 protein
levels were also reported in the previous studies highlighting the ability of
DAC to induce senescence in cancer cells in the same range of
concentrations [30,31]. Although DAC-treated K-562 and MEG-01
cells exhibit increased CDKN1AmRNA levels, p21 was not detectable at
the protein level andwas not induced byDACexposure (data not shown).
There is increasing evidence that p21 expression may be post-
transcriptionally regulated by microRNAs. In addition, post-translational
regulations and specifically ubiquitin-dependent proteasomal degradation
play a critical role in p21 expression and activity [33]. Therefore, the lack
of p21 protein expression in DAC-treated CML cells could be due to
these mechanisms. Nevertheless, these results demonstrated that p21
overexpression is probably not implicated in DAC-induced senescence.
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Neoplasia Vol. 16, No. 6, 2014 Grandjenette et al. 523Although senescence is mainly associated with G1/G0 or G2/M
arrest [34], we provided evidence that DAC elicits a transitional
accumulation in G2/M in K-562 senescent cells only at day 1 and day
2. Abrogation of cell cycle checkpoint after longer exposure to DAC
may be due to p53 gene inactivation in K-562 cells [35]. No specific
cell cycle arrest was observed in DAC-induced MEG-01 senescent
cells, likely due to the up-regulation of genes involved in the various
stages of cell-cycle progression after DAC exposure. Indeed, in0.0000 
0.0004 
0.0008 
MEG-01 
DAC (days)
0        1        2      3s        3a      4s     4a     6s     6a     
**     
**     
**     
**     
**     
**     
**     
K-562 
DAC (days)
0        1        2      3        4      6     8     h
TE
R
T/
β-a
ct
in
 m
RN
A
hT
ER
T/
β-a
ct
in
 m
RN
A
hT
ER
T/
β-a
ct
in
 m
RN
A
0.000 
0.001 
0.002 
10     
**     
**     
**     **     
**     
**     
0.0000 
0.0001 
0.0002 
KBM-5 
DAC (days)
0        1       2      3        4     6     8     10     13     17
**     
**     
**     **     **     **
D 
*     
Figure 4. (continued).particular, p21WAF1/CIP1 and p27Kip1 may regulate the G1/S as well
as the G2/M checkpoints [36,37].
Telomere shortening has been proposed as an important initiator of
stress-induced premature senescence [38]. Interestingly, our results
indicate that DAC elicits telomere shortening in CML cells. We have
also established that DAC-induced senescence was associated with
hTERT down-regulation resulting in a significant reduction of
telomerase activity in CML cells. So far, only a few studies have
focused on hTERT expression in premature senescent cells. Specifically,
recently, indole-3-carbinol, which is derived by hydrolysis from
glycobrassicin produced in cruciferous vegetables, was shown to trigger
senescence by down-regulating hTERT expression and telomerase
activity in human breast cancer cells [39]. In addition, our results were
in agreement with previous data indicating that DAC exposure may
induce hTERT demethylation, leading to reduced telomerase activity
and hTERT expression [40]. DAC was also described to inhibit
telomerase activity through transcriptional repression of hTERT in
human prostate cancer cells [41]. Therefore, we provided evidence that
DAC decreased telomere length by reducing telomerase activity as well
as hTERT expression in senescent CML cells.
Telomerase counterbalances telomere loss by synthetizing telo-
meric DNA repeats to the 3' end of DNA strands [42]. Malignant
cells are recognized to exhibit telomerase activity in contrast to normal
somatic cells where the activity of this enzyme is mostly inactive thus
leading to a progressive shortening of telomeres [43]. Cancer cells are
described to have short telomeres and to maintain their telomeres
through their increased telomerase activity thus conferring immor-
talization [44]. Accordingly, we provided evidence that telomerase
activity was very low in human normal cells compared to control
CML cells. Our data also indicate that the average telomere length in
K-562 cells was higher than that in normal blood cells. To the best of
our knowledge, only a few studies have compared the telomere length
in CML and normal cells. In contrast to our data, telomere length of
leukemia cells from CML patients was reported to be shorter
compared to the lymphocytes of human normal controls [45]. This
study focused on CML patient cells whereas we evaluated telomere
length in CML cancer cell lines. This consideration could explain the
discrepancy between studies. However, another study in line with our
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Figure 5. DAC reduces hTERT expression through decreased binding of c-myc to the hTERT promoter in CML cells. K-562 cells were
cultured in presence or absence of 2 μM DAC. (A) ChIP analysis of H3K4Me3 and c-myc recruitment to hTERT promoter. (B and C)
Analysis of c-myc expression at protein and mRNA levels. (D) c-myc and hTERT expression at mRNA and protein levels in K-562 cells
transfected with or without control siRNA or c-myc siRNAs. (E and F) Analysis of CDKN2D (p19) expression at protein and mRNA levels.
(G) CDKN2D and c-myc expression were evaluated at mRNA and protein levels in K-562 cells transfected with or without control siRNA or
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524 5-aza-2′-deoxycytidine promotes senescence in CML Grandjenette et al. Neoplasia Vol. 16, No. 6, 2014results has reported that cells from breast cancer patients display
significantly longer telomeres compared to normal cells [46].
Several investigators published that the oncogene c-myc acts as a key
transcriptional activator of hTERT during carcinogenesis [27,47].
In the present study, we demonstrated using siRNA experiments
that c-myc is involved in hTERT transcription in K-562 cells. In
addition, we provided evidence that DAC-mediated c-myc down-
regulation triggers telomere-dependent senescence by regulating
hTERT in CML. Accordingly, c-myc down-regulation was reported
to trigger cellular senescence in solid cancers and lymphoma [48].
Furthermore, genistein, a potent DNA methyltransferase inhibitor,
was described to abrogate hTERT transcriptional activity through
c-myc down-regulation in prostate cancer cells [49].Here, we provided evidence that DAC reduces hTERT expression
through decreased binding of c-myc to the hTERT promoter.
Nevertheless, we do not exclude the contribution of other epigenetic
changes that would result in hTERT down-regulation. Indeed, hTERT
is regulated by several epigenetic alterations at promoter sites including
histone acetylation and promoter methylation [27]. Specifically, several
studies have pointed out that hTERT is hypermethylated in various
adenocarcinoma cell line models and that demethylation of this gene
by 5-azacytidine, another classical demethylating agent, inhibits its
transcription through reactivation of the binding of the transcriptional
repressor CTCF [50]. Here, we showed that DAC induces
demethylation of hTERT promoter within CTCF binding site region.
Therefore, besides abrogating hTERT expression through decreased
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Neoplasia Vol. 16, No. 6, 2014 Grandjenette et al. 525binding of c-myc to the hTERT promoter in CML cells, DAC could
further reduce hTERT expression by DNA demethylation-mediated
CTCF recruitment.
Recent reports demonstrated that CDKN2D may negatively
regulate c-myc transcriptional activity through their physical
interaction [28]. Here, our results indicate that CDKN2D is up-
regulated in DAC-treated CML cells. In this regard, we suggest
that c-myc repression could be due to CDKN2D up-regulation.
Nevertheless, surprisingly, the siRNA-mediated knockdown
of CDKN2D did not alter c-myc at both RNA and protein levels
in K-562 cells. Since CDKN2D basal level is very low in K-562
cells, it is possible that CDKN2D knockdown is not enough to alter
c-myc expression. Further studies are required to clarify whether
CDKN2D physically interacts with c-myc in DAC-induced
senescent CML cells. Nonetheless, besides p19, we cannot rule
out that other regulators of c-myc expression are modulated by DAC
treatment. Indeed, Mxi1, a transcriptional repressor of c-myc, has
been reported to be silenced by DNA methylation in cancer [51].
Similarly, several miRNAs including miR-34a, 34c and Let-7a
targeting c-myc regulation are reported to be silenced by DNA
methylation [13,14,52]. Therefore, further investigations are required
to elucidate themechanisms ofDAC-mediated c-myc down-regulation.
K-562 cells exposed to increasing doses of DAC exhibit CDKN2D
gene overexpression suggesting that effects induced by DAC on this
gene could be related to its epigenetic action. We hypothesized that
the increased expression of CDKN2D could result of direct promoter
demethylation. However, MSP analysis did not reveal any evidence ofCDKN2D promoter methylation in K-562 cells. Consequently, the
mechanism of enhanced CDKN2D expression in DAC-treated K-562
cells remains to be elucidated. In this context, DNA demethylationmay
reactivate genes or transcription factors involved in the regulation of
CDKN2D thus leading to up-regulation of this gene after DAC
treatment. Nevertheless, we showed that overexpression of p19 per se is
not sufficient to induce cellular senescence in K-562 cells (supplemen-
tary information, Figure SI1).
There is increasing evidence that epigenetic mechanisms such as
DNA methylation are involved in the establishment and/or the
maintenance of senescence program [53]. Here, we provided evidence
that DAC treatment triggers cellular senescence in CML cells. We
additionally showed that K-562 cells exposed to increasing doses of
DAC or 5-azacytidine become senescent in a dose-dependent manner
suggesting that senescence induced by these compounds could be
related to demethylating effects. Consistently with our findings, a
recent study reported that DNMT inhibition by 5-azacytidine
induces senescence in stem cells [54].
Standard chemotherapeutic regimens are now recognized to exert
their therapeutic potential not only via forcing cancer cells to die but
also by promoting a terminal arrest program that contributes to the
outcome of cancer therapy as well [55]. It became clear that
senescence functions as a physiological in vivo mechanism to
counteract tumor progression from the early steps of carcinogenesis.
Importantly, senescent tumor cells may be cleared, in vivo, by the
innate immune system, thus resulting in tumor regression [56]. In
this context, the concept of pro-senescence therapy has emerged over
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526 5-aza-2′-deoxycytidine promotes senescence in CML Grandjenette et al. Neoplasia Vol. 16, No. 6, 2014the past few years as a novel therapeutic approach to treat cancer with
or without traditional chemotherapies [6].
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